Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study

ABSTRACT

Objectives: Limited evidence has suggested that cefoperazone-sulbactam causes coagulation disorders and bleeding.

Methods: The authors conducted a retrospective study to compare patients receiving cefoperazone-sulbactam versus those treated with cefoperazone-tazobactam or ceftazidime. Propensity-score matching was used to explore whether treatment with cefoperazone-sulbactam increased the risk of prothrombin time (PT) prolongation, coagulation disorders, and bleeding, or decreased platelets (PLT).

Results: The cohort included 23,242 patients. Among patients receiving cefoperazone-sulbactam, the risk of PT prolongation, coagulation disorders, decreased PLT, and bleeding was 5.3%, 9.2%, 15.7%, and 4.2%, respectively. Propensity-score matching analyses suggested that cefoperazone-sulbactam increased the risk of PT prolongation (aOR 2.26, 95% CI 1.61–3.18), coagulation disorders (aOR 1.81, 95% CI 1.43–2.30), and decreased PLT (aOR 1.46, 95% CI 1.25–1.72), but not increase bleeding (aOR 1.05, 95% CI 0.79–1.40) compared with ceftazidime. Patients receiving cefoperazone-sulbactam had higher risk of PT prolongation (aOR 1.53, 95% CI 1.11–2.10), coagulation disorders (aOR 1.53, 95% CI 1.21–1.95), but not decreased PLT (aOR 0.93, 95% CI 0.81–1.07) or bleeding (aOR 1.11, 95% CI 0.87–1.42), compared with those receiving cefoperazone-tazobactam.

Conclusion: Cefoperazone-sulbactam may be associated with a higher risk of PT prolongation and coagulation disorders compared with cefoperazone-tazobactam and ceftazidime.     

脓毒症的诊断与治疗

近年来对于脓毒症及其并发症的认识和治疗研究有了很大进展,但严重的脓毒症、脓毒性休克的死亡率仍高达30%~50%,特别是真菌菌血症病死率高达50%。本文概述脓毒症的概念和诊断,着重从早期目标治疗、血管收缩药物的应用、抗生素的使用、控制感染源、肾上腺皮质激素的应用、机械通气策略、重组人活化蛋白C的应用、镇静剂和止痛剂及神经肌肉阻断剂的使用、脓毒症的辅助治疗和支持治疗等方面阐述脓毒症的治疗进展。希望能引起临床工作者对脓毒症的重视,提高脓毒症患者的生存率。     

现代教育技术在执业药师远程继续教育中的应用研究

利用计算机技术，搭建执业药师网上远程继续教育的平台，将主管部门审核的有关执业药师继续教育的教学内容放到网上，供参加执业药师继续教育的人员浏览学习。通过加强管理，严格考核，变传统教学模式为现代教育方式，实现教育的个性化，有效提高执业药师的继续教育质量。     

主动脉瘤腔内隔绝术

主动脉的扩张性疾病可分为真性动脉瘤、动脉夹层（aortic dissection，AD）和假性动脉瘤。随着这类疾病发病率和检出率逐年提高，人们对它们的关注程度也不断提高。如何治疗他们，成为摆在临床医生面前的难题。1991年，Parodi率先报告了支架-人造血管复合体（直型）在腹主动脉瘤治疗中的应用，成为腔内血管治疗历史上的一个里程碑。随着医疗器械的不断发展、技术的不断完善、经验的不断积累总结，微创、安全的腔内隔绝术在主动脉扩张性疾病中的治疗中得到广泛的认可，并在全球范围内迅速推广。     

枳椇子总黄酮提取工艺及其解酒作用

分别用水和乙醇作为溶剂加热提取枳椇子中的总黄酮,用比色法测定黄酮的含量,分别以提取时间、加热温度、料液比、提取次数等因素进行正交试验.对两种提取方法进行比较,确定各因素对提取效果的影响并对其解酒作用进行研究.水提取法的最优条件是：100 ℃,料液比1 g：8 mL,加热0.5 h,回流提取3次;醇提取法的最佳条件：80 ℃,料液比1 g：6 mL,加热1.5 h,以体积分数50%的乙醇回流提取3次.实验结果显示,醇提取法比水提取法效果更好,枳椇子提取液具有一定的解酒作用.